The New Math: How VC and PE Are Rethinking Capital in Women's Health
Presented during New York Tech Week
Women's health is having a moment—but the capital backing it remains uneven. Investors are paying unprecedented attention to the category, driven by its scale, its underserved patient base, and a wave of clinical and commercial validation. Yet beneath the surface, the financing landscape is anything but straightforward. Capital remains concentrated in a small number of high-profile deals, early- and growth-stage companies face persistent cliffs, and founders often find themselves navigating a mismatch between the businesses they're building and the investment models available to them.
Meanwhile, the investors themselves are evolving. Venture capital is recalibrating its timelines, its risk tolerance, and its assumptions about what constitutes a durable women's health business. Private equity is playing an increasingly central role, building platforms and infrastructure with a fundamentally different approach to value creation and scale. These two worlds—once distinct—are beginning to converge in ways that could redefine how women's health companies are financed, operated, and brought to market. The question is no longer whether this sector matters. It's what kind of capital will shape its next chapter.
This panel brings together venture and private equity investors active in or adjacent to women's health to explore:
👉🏼 Where the capital is really going—and where it isn't
👉🏼 How investors assess opportunity across stages, sectors, and business models
👉🏼 The trade-offs between speed, scale, and sustainability in today's approaches
👉🏼 Whether hybrid VC/PE models are emerging—and how founders should prepare
👉🏼 What the current dynamics mean for the next generation of women's health companies
This is a candid, strategic conversation for investors, founders, and ecosystem builders who want a clear-eyed view of where women's health investing stands today—and where it's headed next.
🔅 Who Should Attend: Investors across venture, growth equity, and private equity; founders and operators in women's health and healthcare services; limited partners with healthcare mandates; and ecosystem builders interested in the intersection of capital strategy and care delivery.